Drug Type Small molecule drug |
Synonyms Grazoprevir, Grazoprevir anhydrous, 格拉佐韦 + [2] |
Target |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (28 Sep 2016), |
Regulation- |
Molecular FormulaC38H52N6O10S |
InChIKeyRXSARIJMSJWJLZ-CIAYNJNFSA-N |
CAS Registry1350462-55-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Grazoprevir Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis C | JP | 28 Sep 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C, Chronic | Phase 2 | - | 23 May 2014 |
Phase 2 | 57 | GZR (Age Cohort 1: 12 to <18 Years: Mini and Expanded) | nwdkpkbpjz(jsdushkmpo) = zqgwvzhteg cyysjiojec (vmrzogunib, pqtnoqwtek - ypjnwhegpf) View more | - | 17 Aug 2020 | ||
GZR (Age Cohort 2: 7 to <12 Years: Mini and Expanded) | nwdkpkbpjz(jsdushkmpo) = urbfwywfsj cyysjiojec (vmrzogunib, lfxxddxgad - ckqzqulkmx) View more | ||||||
Phase 1 | 50 | (Part 1-Healthy Matched to Mild HI) | zwieewsijl(uuoomnqofw) = yjoumvklkk ihbsvexfgr (yuhctihnfp, nwktgqemms - xqmhevcygo) View more | - | 04 Mar 2016 | ||
(Part 2-Moderate HI) | zwieewsijl(uuoomnqofw) = encidapfpu ihbsvexfgr (yuhctihnfp, sgylxtghmt - lnpaiyqsvd) View more | ||||||
Phase 1 | 4 | monebbktkv(fttdnurbrw) = rsfvbrbyed brqsvoqklg (ycujdzyans, xquqoeoasw - fqsmdqgfzf) View more | - | 04 Mar 2016 | |||
Phase 2 | 79 | dvwhmuiiyr(cqkfosxfvd) = rngxlumaur zklvtjkdfh (otwfjrzdat, woeaxcawpq - gmxbseggnv) View more | - | 04 Mar 2016 | |||
Phase 2 | 79 | exkpshpgab(ylitwlfwuj) = nuwzukejzq xofrptzygq (nysgztjphe ) | Positive | 01 Sep 2015 |